Research Analysts Offer Predictions for BPMC FY2024 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Equities researchers at Zacks Research issued their FY2024 EPS estimates for Blueprint Medicines in a research note issued to investors on Monday, November 18th. Zacks Research analyst A. Chakraborty expects that the biotechnology company will earn ($3.87) per share for the year. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.66) per share. Zacks Research also issued estimates for Blueprint Medicines’ Q4 2024 earnings at ($0.86) EPS, Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($2.37) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.07 EPS and FY2026 earnings at $0.25 EPS.

BPMC has been the topic of several other reports. Baird R W raised shares of Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. JMP Securities reissued a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Monday. UBS Group initiated coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 target price on the stock. Wells Fargo & Company lowered their target price on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Finally, Guggenheim raised their price target on shares of Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $122.11.

Blueprint Medicines Trading Up 2.0 %

BPMC stock opened at $96.66 on Thursday. The company’s 50-day simple moving average is $90.26 and its 200-day simple moving average is $98.69. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. Blueprint Medicines has a 52-week low of $65.68 and a 52-week high of $121.90. The firm has a market cap of $6.14 billion, a P/E ratio of -45.81 and a beta of 0.59.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same period in the prior year, the company posted ($2.20) EPS. The company’s revenue for the quarter was up 126.5% on a year-over-year basis.

Institutional Trading of Blueprint Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank increased its holdings in Blueprint Medicines by 5.3% in the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 109 shares during the last quarter. Van ECK Associates Corp increased its holdings in Blueprint Medicines by 13.3% in the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 131 shares during the last quarter. EFG Asset Management North America Corp. increased its holdings in Blueprint Medicines by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock valued at $3,008,000 after purchasing an additional 132 shares during the last quarter. Pallas Capital Advisors LLC increased its holdings in Blueprint Medicines by 3.2% in the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock valued at $523,000 after purchasing an additional 176 shares during the last quarter. Finally, US Bancorp DE increased its holdings in Blueprint Medicines by 5.2% in the 1st quarter. US Bancorp DE now owns 3,724 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 183 shares during the last quarter.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Fouad Namouni sold 3,633 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares in the company, valued at $6,169,332.40. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.21% of the stock is owned by insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.